Miki Koroku 1, Teppei Omori 1, Harutaka Kambayashi 1, Shun Murasugi 1, Tomoko Kuriyama 1, Yuichi Ikarashi 1, Maria Yonezawa 1, Ken Arimura 2, Kazunori Karasawa 3, Norio Hanafusa 4, Masatoshi Kawana 5, Katsutoshi Tokushige
Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report
Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.
Contact UsFor more informationContact Us